BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21723015)

  • 1. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 2. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 3. [Questions and answers about bisphosphonates].
    Letonturier P
    Presse Med; 2007 Mar; 36(3 Pt 1):440. PubMed ID: 17436449
    [No Abstract]   [Full Text] [Related]  

  • 4. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 5. Immediate Implant Placement in a Patient With Osteoporosis Undergoing Bisphosphonate Therapy: 1-Year Preliminary Prospective Study.
    Siebert T; Jurkovic R; Statelova D; Strecha J
    J Oral Implantol; 2015 Jul; 41 Spec No():360-5. PubMed ID: 24041299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
    Lee CY; Suzuki JB
    Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
    Sonis ST; Watkins BA; Lyng GD; Lerman MA; Anderson KC
    Oral Oncol; 2009 Feb; 45(2):164-72. PubMed ID: 18715819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 9. Sore mandible. Bisphosphonate-associated osteonecrosis.
    Damm DD; Fantasia JE
    Gen Dent; 2006; 54(5):370, 372. PubMed ID: 17004575
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
    López-Cedrún JL; Sanromán JF; García A; Peñarrocha M; Feijoo JF; Limeres J; Diz P
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):874-9. PubMed ID: 23866309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk.
    Kos M; Kuebler JF; Luczak K; Engelke W
    J Craniomaxillofac Surg; 2010 Jun; 38(4):255-9. PubMed ID: 19592261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
    Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathological fractures in patients caused by bisphosphonate-related osteonecrosis of the jaws: report of 3 cases.
    Wongchuensoontorn C; Liebehenschel N; Wagner K; Fakler O; Gutwald R; Schmelzeisen R; Sauerbier S
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1311-6. PubMed ID: 19446222
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.
    Herbozo PJ; Briones DL; Ferres AJ; Torrealba RL
    J Oral Maxillofac Surg; 2007 Aug; 65(8):1650-4. PubMed ID: 17656297
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors in the Development of Oral Bisphosphonate-induced Osteonecrosis.
    Reiss S; Sultan D
    N Y State Dent J; 2015 Nov; 81(6):30-3. PubMed ID: 26749781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposed bone in bisphosphonate-related osteonecrosis of the jaws may be induced and maintained by localized microbial biofilm osteomyelitis.
    Lumerman HS
    J Oral Maxillofac Surg; 2013 Dec; 71(12):2011. PubMed ID: 24128706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.